Skip to main content
SpringerLink
Log in

Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein–protein interaction

  • Published:
Journal of Computer-Aided Molecular Design Aims and scope Submit manuscript

Abstract

Targeting of MDM2-p53 protein–protein interaction is a current approach for the development of potent anticancer agents. The classical pharmacophore hypothesis for the design of such molecules describes the three point binding of a small molecule inhibitor to the MDM2 protein. However, this hypothesis is not confirmed when considering the activity of a number of known potent MDM2 inhibitors. Here we demonstrate the important role of the flexible N-terminal region of the MDM2 protein in the binding with small molecule compounds, which contributes to the transition from three point binding to four point binding during the development of new anticancer agents. To evaluate the contribution of the MDM2 N-terminal region to the structure–activity relationship of known MDM2 inhibitors, compounds of nutlin series, whose spatial configuration was shown to dramatically affect the target activity, were used as objects of the study. The key amino acid residues within the N-terminal region involved in the interaction with small molecule ligands were determined by means of molecular dynamics. The conformational stability of the flexible MDM2 fragment was simulated under different conditions. The effects of point mutations on the N-terminal region stability were also demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15

Similar content being viewed by others

References

  1. Nowsheen S, Yang ES (2012) The intersection between DNA damage response and cell death pathways. Exp Oncol 34:243–254

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299

    Article  CAS  Google Scholar 

  3. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25–27

    Article  CAS  Google Scholar 

  4. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299–303

    Article  CAS  Google Scholar 

  5. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137:609–622

    Article  CAS  Google Scholar 

  6. Shi D, Gu W (2012) Dual roles of MDM2 in the regulation of p53: ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer 3:240–248

    Article  CAS  Google Scholar 

  7. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794–799

    CAS  PubMed  Google Scholar 

  8. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, Barbareschi M (1995) Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175:31–38

    Article  CAS  Google Scholar 

  9. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, Bevilacqua G (1995) Mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4:93–97

    Article  CAS  Google Scholar 

  10. Saha MN, Qiu L, Chang H (2013) Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 6:23

    Article  CAS  Google Scholar 

  11. Krasavin M, Gureyev MA, Dar’in D, Bakulina O, Chizhova M, Lepikhina A, Novikova D, Grigoreva T, Ivanov G, Zhumagalieva A, Garabadzhiu AV, Tribulovich VG (2018) Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction. Bioorg Med Chem 26:2651–2673

    Article  CAS  Google Scholar 

  12. Davidovich P, Aksenova V, Petrova V, Tentler D, Orlova D, Smirnov S, Gurzhiy V, Okorokov AL, Garabadzhiu A, Melino G, Barlev N, Tribulovich V (2015) Discovery of novel isatin-based p53 inducers. ACS Med Chem Lett 6:856–860

    Article  CAS  Google Scholar 

  13. Grigoreva TA, Novikova DS, Gureev MA, Garabadzhiu AV, Tribulovich VG (2018) Amino acids as chiral derivatizing agents for antiproliferative substituted N-benzyl isoindolinones. Chirality 30:785–797

    Article  CAS  Google Scholar 

  14. Ribeiro CJ, Rodrigues CM, Moreira R, Santos MM (2016) Chemical variations on the p53 reactivation theme. Pharmaceuticals (Basel) 9:E25

    Article  Google Scholar 

  15. Michelsen K, Jordan JB, Lewis J, Long AM, Yang E, Rew Y, Zhou J, Yakowec P, Schnier PD, Huang X, Poppe L (2012) Ordering of the N-terminus of human MDM2 by small molecule inhibitors. J Am Chem Soc 134:17059–17067

    Article  CAS  Google Scholar 

  16. Grigoreva TA, Garabadzhiu AV, Tribulovich VG (2016) Diastereotopic derivatives of chiral alkoxyisoindolinones. Russ J Gen Chem 86:2454–2461

    Article  CAS  Google Scholar 

  17. Grigoreva TA, Novikova DS, Petukhov AV, Gureev MA, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG (2017) Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors. Bioorg Med Chem Lett 27:5197–5202

    Article  CAS  Google Scholar 

  18. Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T (2006) Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg Med Chem Lett 16:3310–3314

    Article  CAS  Google Scholar 

  19. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848

    Article  CAS  Google Scholar 

  20. Anil B, Riedinger C, Endicott JA, Noble ME (2013) The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallogr D Biol Crystallogr 69:1358–1366

    Article  CAS  Google Scholar 

  21. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748

    Article  CAS  Google Scholar 

  22. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA (2004) A hierarchical approach to all-atom protein loop prediction. Proteins 55:351–367

    Article  CAS  Google Scholar 

  23. Jacobson MP, Friesner RA, Xiang Z, Honig B (2002) On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 320:597–608

    Article  CAS  Google Scholar 

  24. Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL, Kaus JW, Cerutti DS, Krilov G, Jorgensen WL, Abel R, Friesner RA (2016) OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 12:281–296

    Article  CAS  Google Scholar 

  25. Toukan K, Rahman A (1985) Molecular-dynamics study of atomic motions in water. Phys Rev B 31:2643–2648

    Article  CAS  Google Scholar 

  26. Bueren-Calabuig JA, Michel J (2016) Impact of Ser17 phosphorylation on the conformational dynamics of the oncoprotein MDM2. Biochemistry 55:2500–2509

    Article  CAS  Google Scholar 

  27. Zheng J, Lang Y, Zhang Q, Cui D, Sun H, Jiang L, Chen Z, Zhang R, Gao Y, Tian W, Wu W, Tang J, Chen Z (2015) Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation. Genes Dev 29:1524–1534

    Article  CAS  Google Scholar 

  28. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, Fischer P, McInnes C, Barlow PN (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350:587–598

    Article  CAS  Google Scholar 

  29. Shin JS, Ha JH, Lee DH, Ryu KS, Bae KH, Park BC, Park SG, Yi GS, Chi SW (2015) Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition. Cell Cycle 14:533–543

    Article  CAS  Google Scholar 

  30. Worrall EG, Wawrzynow B, Worrall L, Walkinshaw M, Ball KL, Hupp TR (2009) Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J Chem Biol 2:113–129

    Article  Google Scholar 

  31. Dastidar SG, Raghunathan D, Nicholson J, Hupp TR, Lane DP, Verma CS (2011) Chemical states of the N-terminal “lid” of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle 10:82–89

    Article  CAS  Google Scholar 

  32. Verkhivker GM (2012) Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics. PLoS ONE 7:e40897

    Article  CAS  Google Scholar 

  33. Zhan C, Varney K, Yuan W, Zhao L, Lu W (2012) Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined. J Am Chem Soc 134:6855–6864

    Article  CAS  Google Scholar 

  34. Showalter SA, Bruschweiler-Li L, Johnson E, Zhang F, Brüschweiler R (2008) Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J Am Chem Soc 130:6472–6478

    Article  CAS  Google Scholar 

  35. Thompson T, Andreeff M, Studzinski GP, Vassilev LT (2010) 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol Cancer Ther 9:1158–1168

    Article  CAS  Google Scholar 

  36. Fry DC, Wartchow C, Graves B, Janson C, Lukacs C, Kammlott U, Belunis C, Palme S, Klein C, Vu B (2013) Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. ACS Med Chem Lett 4:660–665

    Article  CAS  Google Scholar 

  37. Fedorova O, Daks A, Petrova V, Petukhov A, Lezina L, Shuvalov O, Davidovich P, Kriger D, Lomert E, Tentler D, Kartsev V, Uyanik B, Tribulovich V, Demidov O, Melino G, Barlev NA (2018) Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis. Cell Cycle 17:1917–1930

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was financially supported by the Russian Science Foundation (Project No. 16-13-10358).

Author information

Authors and Affiliations

  1. Laboratory of Molecular Pharmacology, Saint Petersburg State Institute of Technology, 26 Moskovskii pr, Saint Petersburg, 190013, Russia

    Maxim Gureev, Daria Novikova, Tatyana Grigoreva, Svetlana Vorona, Alexander Garabadzhiu & Vyacheslav Tribulovich

Authors
  1. Maxim Gureev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daria Novikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatyana Grigoreva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Svetlana Vorona
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander Garabadzhiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vyacheslav Tribulovich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vyacheslav Tribulovich.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gureev, M., Novikova, D., Grigoreva, T. et al. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein–protein interaction. J Comput Aided Mol Des 34, 55–70 (2020). https://doi.org/10.1007/s10822-019-00260-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10822-019-00260-6

Keywords

Search

Navigation